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Abstract
Problem/Condition: Elevated blood lead levels (BLLs) in adults can damage the cardiovascular, central nervous,
reproductive, hematologic, and renal systems. The majority of cases are workplace-related. U.S. Department of Health
and Human Services recommends that BLLs among all adults be reduced to <25 µg/dL. The highest BLL acceptable by
standards of the U.S. Occupational Safety and Health Administration is 40 µg/dL. The mean BLL of adults in the
United States is <3 µg/dL.
Reporting Period: This report covers cases of adults (aged >16 years) with BLLs >25 µg/dL, as reported by 25 states
during 1998–2001.
Description of System: Since 1987, CDC has sponsored the state-based Adult Blood Lead Epidemiology and Surveil-
lance (ABLES) program to track cases of elevated BLLs and provide intervention consultation and other assistance.
Overall ABLES program data were last published in 1999 for the years 1994–1997. This report provides an update
with data from 25 states reporting for >2 years during 1998–2001. During that period, the ABLES program funded
surveillance in 21 states — Alabama, Arizona, Connecticut, Iowa, Maryland, Massachusetts, Michigan, Minnesota,
New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas,
Washington, Wisconsin, and Wyoming. Four additional states — California, Nebraska, New Hampshire, and Utah —
contributed data without CDC funding.
Results: During 1998–2001, the overall program’s annual mean state prevalence rate for adults with BLLs >25 µg/dL
was 13.4/100,000 employed adults. This compares with 15.2/100,000 for 1994–1997. Yearly rates were 13.8 (1998),
12.9 (1999), 14.3 (2000), and 12.5 (2001).
For adults with BLLs >40 µg/dL, the overall program’s annual mean state prevalence rate during 1998–2001 was 2.9/
100,000 employed adults. This compares with 3.9/100,000 for 1994–1997. Yearly rates were 3.3 (1998), 2.5 (1999),
2.9 (2000), and 2.8 (2001).
Interpretation: Although certain limitations exist, the overall ABLES data indicate a declining trend in elevated BLLs
among employed adults.
Public Health Actions: ABLES-funded states increased from 21 to 35 in 2002, and more detailed reporting require-
ments were put into effect. These, and other improvements, will enable the ABLES program to work more effectively
toward its 2010 target of eliminating all cases of BLLs >25 µg/dL in adults caused by workplace exposures.
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Introduction
Inorganic Lead
Inorganic lead is a bluish gray metal valued since ancient
times because of its useful properties (e.g., low melting point,
pliability, and resistance to corrosion). The ancient Romans
and Greeks first discovered its toxic effects. Lead is ubiqui-
tous in U.S. urban environments because of the widespread
use of lead compounds in industry, gasoline, and paints dur-
ing the 1900s (1–3).
Adult Lead Exposure
Adult exposure to inorganic lead occurs when dust and
fumes are inhaled and when lead from lead-contaminated
hands, food, water, cigarettes, and clothing is ingested. Lead
absorbed through the respiratory and digestive systems is
released into the blood, which distributes the lead through-
out the body. Approximately 90% of total body lead content
is accumulated in the bones, where it is stored for decades.
Lead in bones continues to be released gradually back into the
body after the external environmental exposure occurs (1–3).
Health Effects of Adult Lead Exposure
The adverse health effects of elevated exposure to lead among
adults include damage to the cardiovascular, central nervous,
reproductive, hematologic, and renal systems (1–3). Studies
have reported that adults with blood lead levels (BLLs) of
25–60 µg/dL can exhibit nonspecific symptoms, including
irritability, fatigue, headache, sleep disturbance, decreased
libido, and depressed mood (4). Studies have also reported
adverse health effects, including hypertension, subtle or sub-
clinical central nervous system deficits, and adverse reproduc-
tive outcomes among adults exposed to lead at concentrations
below the existing regulatory exposure limits of 40 µg/dL
(5–9). Although the significance of these subclinical effects
on long-term health continues to be studied, the U.S.
Department of Health and Human Services (DHHS) recom-
mends that BLLs be reduced to <25 µg/dL among all adults
as a preventive health measure (10,11).
Lead readily crosses the placenta. The source of lead expo-
sure for a fetus might be the mother’s recent exposure to lead
or mobilization of lead into the blood during pregnancy from
bone stores because of past exposure. The American Confer-
ence of Governmental Industrial Hygienists (ACGIH) advises
women of child-bearing age, if their BLL is >10 µg/dL, they
are at risk for delivering a child with a BLL >10 µg/dL (12) —
the level of concern in CDC’s pediatric guidelines.
Sources of Adult Lead Exposures
Data reported to the Adult Blood Lead Epidemiology and
Surveillance Program (ABLES), suggest >90% of elevated BLL
cases among adults result from workplace exposure (13,14).
National Health and Nutrition Examination Survey data
indicate that by 1991–1994, the geometric mean BLL of U.S.
adults had dropped to 2.1, 3.1, and 3.4 µg/dL for persons
aged 20–49, 50–69, and >70 years, respectively (15). This
compares with a geometric mean of 13.1 µg/dL for persons
aged 20–74 years for the period 1976–1980 (16).
Although the mean BLL of the entire U.S. population is rela-
tively low, adult workers continue to be exposed to high con-
centrations of lead in >100 industries, including battery
manufacturing, painting, nonferrous smelting, radiator repair,
brass and bronze foundries, pottery production, scrap metal
recycling, firing ranges, and wrecking and demolition (11).
Elevated BLLs among adults can also be caused by expo-
sure to nonoccupational (i.e., ambient or environmental)
sources of lead (e.g., recreational target shooting, home
remodeling, casting bullets and fishing weights, making
stained glass and ceramics, cookware, pica behavior [inges-
tion of nonfood items], traditional remedies, drinking home-
made alcoholic brews, and retaining bullets in or near a
synovial joint). When occupational exposure is not proven or
seems unlikely, clinicians should investigate these factors as
potential cases of elevated BLLs (11).
Adult Blood Lead Epidemiology
and Surveillance Program
Since 1987, CDC’s National Institute for Occupational
Safety and Health (NIOSH) has sponsored ABLES, a state-
based program that tracks laboratory-reported BLLs among
adults, and teams with other agencies to intervene and help
prevent further high-level lead exposures. For states that
report to ABLES, the primary sources of BLL reports are public
and private laboratories; secondary sources are physicians.
ABLES requires that laboratory reporting to the state health
department (or other designee) of BLL results, both occupa-
tional and nonoccupational, be mandatory under state law.
Laboratory reports include basic demographic information
with unique identifiers to differentiate between new and
ongoing cases and to account for multiple reports regarding
the same person. Those reporting are also urged to include
information regarding occupations and industries, lead-related
avocations, and whether the laboratory is approved for occu-
pational lead testing by the Occupational Safety and Health
Administration (OSHA). The minimum BLL reporting
requirement varies from state to state. Moreover, reporting of
all BLLs is encouraged, because these data are useful for
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analyzing exposure trends and for providing the basis for
future ABLES consultation and education on intervention
strategies.
The public health objective of the ABLES program, as stated
in Healthy People 2010, is to reduce the number of persons
with BLLs >25 µg/dL from work exposures; the target is to
reduce that number to zero by 2010 (10). In collaboration
with the ABLES program, the Council of State and Territo-
rial Epidemiologists (CSTE) has adopted a surveillance case
definition: an adult (aged >16 years) with a venous (or com-
parable) BLL >25 µg/dL of whole blood (17).
The ABLES program seeks to accomplish its objective by
continuing to improve its surveillance programs and helping
state health and other agencies to effectively intervene to pre-
vent further lead exposures. Intervention strategies imple-
mented by ABLES-reporting states include conducting
follow-up interviews with physicians, employers, and work-
ers; investigating work sites; delivering technical assistance
regarding exposure reduction or prevention; providing refer-
rals for consultation and enforcement; and developing and
disseminating educational materials and outreach programs.
The educational materials developed by ABLES-reporting
states are listed on, or linked to, the ABLES website.*
The ABLES program is a complete surveillance program
that entails not only enumerating adults with elevated BLLs,
but also analyzing and reporting data, helping appropriate
agencies intervene to prevent further exposures, and testing
the effectiveness of those interventions. State and federal
ABLES participants and partners have published analyses of
their intervention activities (18–22), surveillance data, and
investigations (13,14,23–27).
To coordinate their reporting and intervention activities for
maximum efficiency, state ABLES programs are strongly
encouraged to develop effective working relationships with
the childhood lead prevention programs in their states. An
estimated 2%–3% of children with BLL >10 µg/dL reach those
levels from exposure to lead brought home from the work-
place on the clothes or in the vehicles of their adult caregivers
(23). State ABLES programs are also encouraged to develop
effective working relationships with other federal and state
agencies involved in preventing adult lead poisoning (e.g.,
OSHA, U.S. Department of Housing and Urban Develop-
ment, U.S. Environmental Protection Agency, U.S. Depart-
ment of Transportation, and U.S. Department of Defense).
Overall ABLES program data were last published in the
MMWR in 1999 for 1994–1997 (28). This report provides
data for 1998–2001. This will be the last report for ABLES
data collected under the old aggregate format. Increased data
requirements that took effect in 2002 will track adult BLLs
by age, sex, and industry.
Methods
Biological Indices
The best method for monitoring exposure to lead is mea-
suring BLLs in whole blood, although other biological indi-
ces exist. As the BLL increases, the frequency and severity of
symptoms associated with lead exposure also increase (albeit
with considerable variability). With other indices of lead
exposure, no such specific relationship with symptoms has
been established (1–3). Furthermore, BLL is responsive to
recent exposures — the cases most amenable to preventive
intervention. Among other indices, measurement of proto-
porphyrin (free or zinc protoporphyrin) concentration in red
blood cells can be an accurate indicator of inhibition of heme
synthesis by lead. However, other causes of elevated proto-
porphyrin levels exist (e.g., iron-deficiency anemia and
inflammatory conditions) (29). Lead concentrations can be
measured in urine, teeth, and hair, but these measurements
are not as reliable as BLLs. An experimental technique, radio-
graphic fluorescence, provides a more accurate method for
determining long-term, cumulative lead exposure and the to-
tal body burden of lead (7), but only a limited number of
research facilities in the United States and Canada provide
bone lead measurements.
Testing Requirements
Permissible exposure limits for lead in the workplace and
worker monitoring are regulated by OSHA standards, which
differ slightly for general industry† (30) and the construction
industry§ (31). A detailed comparison of the standards has
been published elsewhere (32). When airborne lead concen-
trations exceed the action level of 30 µg/m3, OSHA requires
medical surveillance, which includes biologic monitoring of
BLLs by an OSHA-approved laboratory. Under the OSHA
general industry standard, workers must be removed from
substantial lead exposure when their BLLs are >60 µg/dL or
when they averaged >50 µg/dL during the previous six months,
or when workers have detected medical conditions that place
them at increased risk for material impairment to health from
lead exposure. After workers have been medically removed,
they may return to work when their BLLs fall to 40 µg/dL.
Thus, 40 µg/dL can be construed as the highest BLL deemed
acceptable under OSHA lead standards.
* Available at http://www.cdc.gov/niosh/ables.html.
† 29 CFR 1910.1025.
§ 29 CFR 1926.62.
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Surveillance Reporting
 In this report, ABLES prevalence is reported according to
two benchmarks: BLLs >25 µg/dL, the limit set by Healthy
People 2010 in its public health objective (10); and >40 µg/
dL, the limit at which OSHA will permit a worker to return
to work after being medically removed. To enable year-to-year
and state-to-state comparisons of ABLES data, adjustments
were made to account for the changing number and roster of
states, and to control for their different populations. Preva-
lence rates were established by expressing cases of BLLs >25
and >40 µg/dL for each reporting state as annual rates per
100,000 persons employed (aged >16 years). State
employment data were obtained from the Bureau of Labor
Statistics, Current Population Survey ¶ (33).
Results
The data reported here are for the 25 state ABLES pro-
grams reporting for >2 years during 1998–2001 (Figure 1).
These data can differ slightly from previous ABLES reports
that included states no longer reporting (states that stopped
reporting and the years they did report: Maine 1994–1998,
Illinois 1994–1996, New Mexico 1997, and Vermont 1994
and 1997).
For 1998–2001, a total of 25 ABLES states reported 41,984
adults with BLLs >25 µg/dL and 8,265 adults with BLLs >40
µg/dL. The yearly totals for BLLs >25 µg/dL were 10,459
(1998) with 24 of 25 states reporting; 10,310 (1999) with 25
states reporting; 11,272 (2000) with 25 states reporting; and
9,943 (2001) with 23 of 25 states reporting (Table 1). The
yearly totals for BLLS >40 µg/dL were 2,071 (1998); 1,933
(1999); 2,252 (2000); and 2,009 (2001) (Table 2).
More populous ABLES states reported more cases (Tables 1
and 2). To illustrate the degree of variance among states, mean
annual percentages by state are presented for adults with BLLs
>25 µg/dL for 1998–2001 (Figure 2). These percentages were
derived by 1) calculating the mean number of annual cases
for each state during 1998–2001; 2) adding those means; and
3) calculating the percentage of this sum of means for each
state. On average, Pennsylvania, Ohio, California, and New
York — when combined — reported 50% of the adult cases
with BLLs >25 µg/dL, whereas Arizona, Oklahoma, South
Carolina, Utah, and Wyoming reported <1% each (Figure 2).
Using the same method for cases with BLLs >40 µg/dL, on
average, the same four populous states, plus North Carolina,
combined to report 55% of the cases, whereas Arizona,
Nebraska, Oklahoma, Utah, and Wyoming reported, on
average, <1% each (Figure 3).
Year-to-year comparisons were enabled by expressing cases
of BLLs >25 and >40 µg/dL for each reporting state as annual
rates per 100,000 persons employed (aged >16 years). Mean
annual state rates for the overall ABLES program were then
calculated for each year during 1998–2001 (Figure 4). State-
to-state comparisons of 1998-2001 data were made in a simi-
lar fashion. The 25 ABLES states are displayed in order of
their 4-year mean annual rates for adults with BLLs >25 µg/dL
(Figure 5). The overall mean for the 25 states for 1998-2001
was 13.4/100,000 employed. ABLES states are also displayed
in order of their 4-year mean annual rates for adults with BLLs
>40 µg/dL (Figure 6). The overall mean for the 25 states for
1998-2001 was 2.9/100,000.
To make state-to-state comparisons of 1998–2001 data with
1994–1997 data, only 20 of the 25 ABLES states — those
that reported for >2 years during both 4-year periods — were
used (Figures 7 and 8). The mean annual rates for each state
were then calculated, as well as the mean annual rates for the
program overall, during each 4-year period. For adults with
BLLs >25 µg/dL, 17 of 20 states reported lower rates for 1998–
2001, compared with 1994–1997 (only Alabama, North Caro-
lina and Maryland reported higher rates). For the ABLES
program overall, the mean annual rates were 15.2/100,000
for 1994–1997 compared with 13.4/100,000 for 1998–2001
(Figure 7). Using the same method for adults with BLLs >40
µg/dL, 16 of 20 states reported lower rates for 1998–2001,
compared with 1994-1997 (only Alabama, North Carolina,
and Pennsylvania reported higher rates; Maryland’s rate did
not change). For the program overall, the mean annual rates
for adults with BLLs >40 µg/dL were 3.9/100,000 for 1994–
1997 and 2.9/100,000 for 1998–2001 (Figure 8).
¶ Available at http://www.bls.gov/lau/staa_7000.pdf.
FIGURE 1. States reporting to the Adult Blood Lead
Epidemiology and Surveillance (ABLES) program for >2 years
— United States, 1998–2001
ABLES program states
(n=25)
Vol. 51 / SS-11 Surveillance Summaries 5
TABLE 1. Adults with blood lead levels >25 µg/dL reported to the Adult Blood Lead Epidemiology and Surveillance (ABLES)
program during 1994–2001 by 25 states
State 1994 1995 1996 1997 1998 1999 2000 2001
Alabama 502 NA* 511 567 549 490 634 578
Arizona 40 148 56 79 91 48 58 35
California 1,347 997 1,010 1,044 900 911 1,001 872
Connecticut 354 262 229 207 118 124 99 77
Iowa NA 533 522 421 309 401 268 432
Maryland 196 178 153 189 162 292 229 205
Massachusetts 755 641 582 507 470 429 368 297
Michigan NA NA NA 136 303 273 235 208
Minnesota NA 467 255 258 264 272 190 244
Nebraska NA NA NA NA NA 143 94 NA
New Hampshire NA NA NA 187 213 174 212 142
New Jersey 744 611 592 567 511 534 572 543
New York 955 850 1,115 1,045 903 948 955 834
North Carolina 224 342 269 362 379 426 475 558
Ohio NA NA 1,367 1,440 1,146 1,090 1,039 1,572
Oklahoma 52 76 94 88 67 46 66 49
Oregon 269 199 204 187 129 170 180 89
Pennsylvania 2,005 2,897 2,862 3,348 2,394 2,031 2,826 2,113
Rhode Island NA NA NA 104 78 67 178 95
South Carolina 367 595 188 189 195 32 60 NA
Texas 387 189 738 687 556 510 554 307
Utah 83 102 57 98 75 41 34 45
Washington 232 241 203 277 152 148 160 120
Wisconsin 713 932 600 528 428 671 738 507
Wyoming NA NA NA 99 67 39 47 21
Total 9,225 10,260 11,607 12,614 10,459 10,310 11,272 9,943
* NA = Not available.
TABLE 2. Adults with blood lead levels >40 µg/dL reported to the Adult Blood Lead Epidemiology and Surveillance (ABLES)
program during 1994–2001 by 25 states
State 1994 1995 1996 1997 1998 1999 2000 2001
Alabama 180 NA* 165 165 142 144 221 217
Arizona 9 39 19 23 16 2 9 8
California 232 196 167 142 150 126 149 134
Connecticut 85 38 29 46 26 21 20 18
Iowa NA 99 100 68 24 37 19 41
Maryland 61 41 39 47 33 77 54 32
Massachusetts 189 158 122 115 99 80 71 49
Michigan NA NA NA 25 72 48 48 36
Minnesota NA 120 92 64 54 48 39 56
Nebraska NA NA NA NA NA 21 12 NA
New Hampshire NA NA NA 48 66 45 53 32
New Jersey 183 121 127 120 116 104 119 113
New York 164 136 230 208 199 205 178 141
North Carolina 137 181 139 207 188 191 289 386
Ohio NA NA 414 384 222 257 304 318
Oklahoma 15 26 35 35 23 18 17 17
Oregon 49 26 38 28 13 27 38 8
Pennsylvania NA NA 506 482 294 242 325 222
Rhode Island NA NA NA 26 24 17 44 25
South Carolina 290 485 94 101 85 4 16 NA
Texas 306 127 163 147 109 111 111 64
Utah 19 18 11 19 16 4 5 14
Washington 75 57 58 65 22 29 38 18
Wisconsin 125 156 95 67 49 68 71 55
Wyoming NA NA NA 36 29 7 2 5
Total 2,119 2,024 2,643 2,668 2,071 1,933 2,252 2,009
* NA = Not available.
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FIGURE 3. Mean annual percentages by state of total adults
with blood lead levels >40 µg/dL as reported by 25 ABLES
program states, 1998–2001*




























FIGURE 2. Mean annual percentages by state of total adults
with blood lead levels >25 µg/dL as reported by 25 ABLES
program states, 1998–2001*





























FIGURE 5. Mean annual rate by state of adults with blood lead
levels >25 µg/dL reported by 25 ABLES program states, 1998–
2001
Overall mean = 13.4






























* Nebraska 2 years of data; South Carolina 3 years of data.
†
Source: Bureau of Labor Statistics, Current Population Survey, 2001.
FIGURE 4. Mean annual state rates of adults with elevated
blood lead levels, as reported by 25 ABLES program states,
1998–2001
* Source: Bureau of Labor Statistics, Current Population Survey, 2001.
†
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FIGURE 6. Mean annual rate by state of adults with blood lead
levels >40 µg/dL reported by 25 ABLES program states, 1998–
2001
* Nebraska, 2 years of data; South Carolina, 3 years of data.
†
Source: Bureau of Labor Statistics, Current Population Survey, 2001.






























Overall mean = 2.9
FIGURE 7. Mean annual rates by state, 1998–2001 compared
with 1994–1997, for adults with blood lead levels >25 µg/dL —
20 ABLES program states reporting data for >2 years in each
period
* Source: Bureau of Labor Statistics, Current Population Survey, 2001.
†
South Carolina, 3 years of data (1998–2001); Ohio, 2 years of data;












































To better illustrate the decline in BLL rates, the mean
annual rates for the overall program are presented for the years
1994–1997 (Figure 9). From 1998 onward, with the excep-
tion of 2000, the rates for adults with BLLs >25 µg/dL
decreased to <14/100,000. Likewise, the rates for adults with
BLLs >40 µg/dL decreased to <3/100,000.
CDC/NIOSH funding has enabled surveillance and inter-
vention activities among ABLES states that have contributed
to the decline in adult BLLs. NIOSH increased its funding
commitment, allowing the ABLES program to expand from
21 to 35 funded states for 2002 (Figure 10). Four of these
additional 14 states were already providing data to ABLES
(California, Nebraska, New Hampshire, and Utah); three
resumed reporting (Illinois, Maine, and New Mexico); and
seven were completely new (Florida, Georgia, Hawaii, Kan-
sas, Kentucky, Missouri, and Montana).
Discussion
This data analysis has certain limitations, including the
numerators and denominators used in calculating the preva-
lence rates. The numerators are the numbers of adults with
BLLs >25 or >40 µg/dL, as reported by the ABLES states.
These numbers are likely underreported because 1) not all
employers provide BLL testing to lead-exposed workers; and
2) to a lesser extent, certain laboratories might not be in com-
pliance with reporting requirements. Additionally, certain
states with workers at risk do not participate.
The denominators are the numbers of persons, aged >16
years, who were employed in the state during the year in ques-
tion. An advantage of using the employed population as the
denominator is that it excludes unemployed adults who have
limited risk for lead exposure. A disadvantage of using the
employed population is that the numbers include those whose
jobs do not involve lead exposures.
State-to-state comparisons have been made in this report
by using the data reported from the states to the ABLES pro-
gram. Questions regarding the specifics of any state’s report-
ing should be addressed to the ABLES contact from that state
(state contacts are available at the ABLES website). Certain
states publish in-depth analyses of their surveillance data,
and these analyses provide the most complete descriptions
(13–14,25–26).
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FIGURE 8. Mean annual rates by state, 1998–2001 compared
with 1994–1997, for adults with blood lead levels >40 µg/dL —
20 ABLES program states reporting data for >2 years in each
period
* Source: Bureau of Labor Statistics, Current Population Survey, 2001.
†
(1998–2001) South Carolina 3 years of data; (1994–1997) Ohio and










































FIGURE 9. Mean annual state rates of adults with elevated
blood lead levels, as reported by ABLES program states, 1994–
2001
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FIGURE 10. States funded for ABLES program by CDC/
National Institute for Occupational Safety and Health — United
States, 2002
Continued funding (21 states)
New funding (14 states)
The decline in BLL rates observed in this analysis depends
on continued, effective intervention and prevention efforts
by ABLES program participants and their partners. For
example,
• In California, high efficiency particulate air-exhausted
power-sanding reduced paint dust exposure by approxi-
mately 80%–90% (18). Also, contractors and their
employees can now make moderate improvements in lead
safety practices if provided extensive training and techni-
cal assistance (19).
• In Michigan, follow up of companies identified with at
least one worker with a BLL of 30–39 µg/dL was deter-
mined to be an effective method for targeting inspections,
leading Michigan OSHA to follow up on all BLLs >25
µg/dL (20).
• In Washington, potentially exposed workers were identi-
fied through hazard surveillance and characterization of
workplace knowledge and practices (through survey and
registry), allowing targeting of resources toward indus-
tries most in need (27).
CDC/NIOSH continues to take steps to improve the
ABLES program. In addition to expanding the program from
21 to 35 states, NIOSH stipulated that future ABLES data
would be collected on an individual rather than aggregate basis.
These individual data, providing information specific to
occupation, industry, sex, and age, will be more useful to the
efforts to reduce BLLs. With NIOSH assistance, persons from
certain ABLES states are also developing clinical/laboratory
guidelines that will help improve identification of lead
Vol. 51 / SS-11 Surveillance Summaries 9
** Available at http://www.cdc.gov/programs/research12.htm.
†† Available at http://www.osha-slc.gov/SLTC/lead/index.html.
§§ Available at http://www.cpwr.com.
exposure and treatment by medical personnel of this often
unrecognized and misunderstood public health problem (11).
At the same time, CDC is working to implement greater stan-
dardization and efficiency for all its surveillance programs,
including ABLES, under the National Electronic Disease Sur-
veillance System.**
Other partners in the effort to reduce BLLs include the fol-
lowing:
• OSHA’s National Emphasis Program to reduce occupa-
tional lead exposures;††
• voluntary lead-reducing initiatives by trade associations
(e.g., Lead Industries Association Incorporated and Bat-
tery Council International);
• lead research and training programs for the construction
industry offered by the Center to Protect Workers’
Rights;§§ and
• lead initiatives taken by CSTE. In addition to collaborat-
ing with ABLES in developing the case definition for
elevated BLLs among adults (17), CSTE also adopted
the position that ABLES be designated the initial core
component of state-based occupational health and safety
surveillance (34), and coordinated development with
ABLES of the CSTE occupational health surveillance
indicator for lead (35). CSTE advocates that these occu-
pational health surveillance indicators be collected in all
50 states and U.S. territories. CSTE has also called for a
tightening of OSHA’s lead standards (36).
Despite limitations and variations within the ABLES pro-
gram, data indicate a declining trend in the number of adults
with elevated BLLs. Because the program has increased in size
and with the addition of more detailed reporting requirements,
ABLES has increased its capability to offer data, intervention
insights, and other assistance as it works toward its Healthy
People 2010 target of eliminating work-related BLLs >25 µg/dL
among all adults by 2010 (10).
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